Related Experiment Video
Updated: Jun 19, 2026

Yeast As a Chassis for Developing Functional Assays to Study Human P53
Published on: August 4, 2019
Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
Vladimir J N Bykov1, Natalia Issaeva, Alexandre Shilov
1Karolinska Institutet, Department of Oncology-Pathology, Cancer Center Karolinska, Karolinska Hospital, Stockholm, Sweden.
Abstract:
The tumor suppressor p53 inhibits tumor growth primarily through its ability to induce apoptosis. Mutations in p53 occur in at least 50% of human tumors. We hypothesized that reactivation of mutant p53 in such tumors should trigger massive apoptosis and eliminate the tumor cells. To test this, we screened a library of low-molecular-weight compounds in order to identify compounds that can restore wild-type function to mutant p53. We found one compound capable of inducing apoptosis in human tumor cells through restoration of the transcriptional transactivation function to mutant p53. This molecule, named PRIMA-1, restored sequence-specific DNA binding and the active conformation to mutant p53 proteins in vitro and in living cells. PRIMA-1 rescued both DNA contact and structural p53 mutants. In vivo studies in mice revealed an antitumor effect with no apparent toxicity. This molecule may serve as a lead compound for the development of anticancer drugs targeting mutant p53.
Insights
Researchers identified PRIMA-1, a compound that restores the function of mutant p53 proteins. This reactivation triggers cancer cell death, offering a potential new strategy for developing anticancer drugs targeting tumors with p53 mutations.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- The tumor suppressor p53 is crucial for inhibiting tumor growth by inducing apoptosis.
- Mutations in the p53 gene are prevalent in over 50% of human cancers.
- Reactivating mutant p53 could potentially eliminate tumor cells by triggering apoptosis.
Purpose of the Study:
- To identify compounds that can restore wild-type function to mutant p53.
- To evaluate the therapeutic potential of such compounds in cancer treatment.
Main Methods:
- Screening a library of low-molecular-weight compounds.
- Testing compound efficacy in inducing apoptosis in human tumor cells.
- Assessing the restoration of p53 DNA binding and conformation in vitro and in vivo.
- Evaluating antitumor effects and toxicity in mouse models.
Main Results:
- One compound, PRIMA-1, was identified that restores transcriptional transactivation function to mutant p53.
- PRIMA-1 restored sequence-specific DNA binding and active conformation to both DNA contact and structural p53 mutants.
- In vivo studies demonstrated significant antitumor effects with no apparent toxicity.
Conclusions:
- PRIMA-1 effectively reactivates mutant p53, leading to cancer cell apoptosis.
- This molecule shows promise as a lead compound for novel anticancer drug development targeting p53 mutations.
Related Concept Videos
Negative Regulator Molecules
DNA Damage can Stall the Cell Cycle
Abnormal Proliferation
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
DNA Damage Can Stall the Cell Cycle
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...

